AAPL321.66-4.23 (-1.30%) ▼|ABBV256.92+3.62 (+1.43%) ▲|ABT100.75+0.18 (+0.18%) ▲|ACN138.74-1.35 (-0.96%) ▼|ADBE212.17-6.19 (-2.83%) ▼|AMAT562.80+8.88 (+1.60%) ▲|AMD539.69-12.64 (-2.29%) ▼|AMGN371.50+5.45 (+1.49%) ▲|AMT164.65-1.41 (-0.85%) ▼|AMZN233.66-11.19 (-4.57%) ▼|AVGO392.47-4.34 (-1.09%) ▼|AXP340.84-7.90 (-2.27%) ▼|BA209.23+0.58 (+0.28%) ▲|BAC61.28-0.34 (-0.55%) ▼|BKNG172.83-5.03 (-2.83%) ▼|BLK1,037.16-19.47 (-1.84%) ▼|BMY61.51+0.75 (+1.23%) ▲|BNY160.11-0.28 (-0.17%) ▼|BRK-B490.85+1.46 (+0.30%) ▲|C131.88-0.37 (-0.28%) ▼|CAT894.54+5.23 (+0.59%) ▲|CL90.08-1.55 (-1.69%) ▼|CMCSA21.92-1.60 (-6.80%) ▼|COF199.96-1.40 (-0.70%) ▼|COP120.20+1.41 (+1.19%) ▲|COST926.06-1.25 (-0.13%) ▼|CRM156.93-6.07 (-3.72%) ▼|CSCO112.76+0.55 (+0.49%) ▲|CVS106.89-0.53 (-0.49%) ▼|CVX194.42+1.44 (+0.75%) ▲|DE610.02+2.69 (+0.44%) ▲|DHR192.50+13.36 (+7.46%) ▲|DIS92.83-3.04 (-3.17%) ▼|DUK129.26+1.31 (+1.02%) ▲|EMR144.90+5.27 (+3.77%) ▲|FDX315.62-5.40 (-1.68%) ▼|GD381.79+8.63 (+2.31%) ▲|GE349.00+7.81 (+2.29%) ▲|GEV1,031.19+46.16 (+4.69%) ▲|GILD130.86+0.52 (+0.40%) ▲|GM80.67-1.46 (-1.78%) ▼|GOOG318.34-23.57 (-6.89%) ▼|GOOGL317.69-24.40 (-7.13%) ▼|GS1,074.72-23.48 (-2.14%) ▼|HD324.71-6.74 (-2.03%) ▼|HON246.27+13.28 (+5.70%) ▲|IBM206.65+0.88 (+0.43%) ▲|INTC100.23-2.39 (-2.33%) ▼|INTU281.53-2.94 (-1.03%) ▼|ISRG332.02-8.67 (-2.54%) ▼|JNJ259.27+3.64 (+1.42%) ▲|JPM349.90+1.69 (+0.49%) ▲|KO81.17-1.03 (-1.25%) ▼|LIN506.32-2.35 (-0.46%) ▼|LLY1,185.87+22.86 (+1.97%) ▲|LMT568.59+54.23 (+10.54%) ▲|LOW201.92-2.43 (-1.19%) ▼|LRCX319.78+0.49 (+0.15%) ▲|MA530.29-1.69 (-0.32%) ▼|MCD262.80-0.77 (-0.29%) ▼|MDLZ60.05-0.81 (-1.33%) ▼|MDT82.01+0.12 (+0.15%) ▲|META606.10-21.07 (-3.36%) ▼|MMM169.59-1.17 (-0.69%) ▼|MO72.08-0.09 (-0.12%) ▼|MRK130.48+3.01 (+2.36%) ▲|MS215.18-3.32 (-1.52%) ▼|MSFT381.58-8.76 (-2.24%) ▼|MU990.21+30.73 (+3.20%) ▲|NEE89.79+0.38 (+0.43%) ▲|NFLX68.89+0.36 (+0.53%) ▲|NKE40.99-1.22 (-2.89%) ▼|NOW91.94-3.52 (-3.69%) ▼|NVDA208.76-3.30 (-1.56%) ▼|ORCL120.04-5.80 (-4.61%) ▼|PEP134.95-0.70 (-0.52%) ▼|PFE25.01+0.19 (+0.77%) ▲|PG146.97-2.16 (-1.45%) ▼|PLTR123.37-1.20 (-0.96%) ▼|PM191.12-3.18 (-1.64%) ▼|QCOM171.11-4.52 (-2.57%) ▼|RTX209.16+14.28 (+7.33%) ▲|SBUX103.21-0.77 (-0.74%) ▼|SCHW101.61+0.81 (+0.80%) ▲|SO96.60+0.80 (+0.84%) ▲|SPG225.20-1.02 (-0.45%) ▼|T22.96-0.08 (-0.35%) ▼|TMO572.32+45.86 (+8.71%) ▲|TMUS170.42-20.52 (-10.75%) ▼|TSLA319.69-54.32 (-14.52%) ▼|TXN284.99-9.20 (-3.13%) ▼|UBER68.91-1.42 (-2.02%) ▼|UNH423.56-7.75 (-1.80%) ▼|UNP304.33+11.77 (+4.02%) ▲|UPS114.10-1.74 (-1.50%) ▼|USB63.33-1.14 (-1.77%) ▼|V351.60-1.82 (-0.52%) ▼|VZ43.82-0.47 (-1.06%) ▼|WFC86.19-0.23 (-0.27%) ▼|WMT108.40-0.93 (-0.85%) ▼|XOM156.89+2.44 (+1.58%) ▲|AAPL321.66-4.23 (-1.30%) ▼|ABBV256.92+3.62 (+1.43%) ▲|ABT100.75+0.18 (+0.18%) ▲|ACN138.74-1.35 (-0.96%) ▼|ADBE212.17-6.19 (-2.83%) ▼|AMAT562.80+8.88 (+1.60%) ▲|AMD539.69-12.64 (-2.29%) ▼|AMGN371.50+5.45 (+1.49%) ▲|AMT164.65-1.41 (-0.85%) ▼|AMZN233.66-11.19 (-4.57%) ▼|AVGO392.47-4.34 (-1.09%) ▼|AXP340.84-7.90 (-2.27%) ▼|BA209.23+0.58 (+0.28%) ▲|BAC61.28-0.34 (-0.55%) ▼|BKNG172.83-5.03 (-2.83%) ▼|BLK1,037.16-19.47 (-1.84%) ▼|BMY61.51+0.75 (+1.23%) ▲|BNY160.11-0.28 (-0.17%) ▼|BRK-B490.85+1.46 (+0.30%) ▲|C131.88-0.37 (-0.28%) ▼|CAT894.54+5.23 (+0.59%) ▲|CL90.08-1.55 (-1.69%) ▼|CMCSA21.92-1.60 (-6.80%) ▼|COF199.96-1.40 (-0.70%) ▼|COP120.20+1.41 (+1.19%) ▲|COST926.06-1.25 (-0.13%) ▼|CRM156.93-6.07 (-3.72%) ▼|CSCO112.76+0.55 (+0.49%) ▲|CVS106.89-0.53 (-0.49%) ▼|CVX194.42+1.44 (+0.75%) ▲|DE610.02+2.69 (+0.44%) ▲|DHR192.50+13.36 (+7.46%) ▲|DIS92.83-3.04 (-3.17%) ▼|DUK129.26+1.31 (+1.02%) ▲|EMR144.90+5.27 (+3.77%) ▲|FDX315.62-5.40 (-1.68%) ▼|GD381.79+8.63 (+2.31%) ▲|GE349.00+7.81 (+2.29%) ▲|GEV1,031.19+46.16 (+4.69%) ▲|GILD130.86+0.52 (+0.40%) ▲|GM80.67-1.46 (-1.78%) ▼|GOOG318.34-23.57 (-6.89%) ▼|GOOGL317.69-24.40 (-7.13%) ▼|GS1,074.72-23.48 (-2.14%) ▼|HD324.71-6.74 (-2.03%) ▼|HON246.27+13.28 (+5.70%) ▲|IBM206.65+0.88 (+0.43%) ▲|INTC100.23-2.39 (-2.33%) ▼|INTU281.53-2.94 (-1.03%) ▼|ISRG332.02-8.67 (-2.54%) ▼|JNJ259.27+3.64 (+1.42%) ▲|JPM349.90+1.69 (+0.49%) ▲|KO81.17-1.03 (-1.25%) ▼|LIN506.32-2.35 (-0.46%) ▼|LLY1,185.87+22.86 (+1.97%) ▲|LMT568.59+54.23 (+10.54%) ▲|LOW201.92-2.43 (-1.19%) ▼|LRCX319.78+0.49 (+0.15%) ▲|MA530.29-1.69 (-0.32%) ▼|MCD262.80-0.77 (-0.29%) ▼|MDLZ60.05-0.81 (-1.33%) ▼|MDT82.01+0.12 (+0.15%) ▲|META606.10-21.07 (-3.36%) ▼|MMM169.59-1.17 (-0.69%) ▼|MO72.08-0.09 (-0.12%) ▼|MRK130.48+3.01 (+2.36%) ▲|MS215.18-3.32 (-1.52%) ▼|MSFT381.58-8.76 (-2.24%) ▼|MU990.21+30.73 (+3.20%) ▲|NEE89.79+0.38 (+0.43%) ▲|NFLX68.89+0.36 (+0.53%) ▲|NKE40.99-1.22 (-2.89%) ▼|NOW91.94-3.52 (-3.69%) ▼|NVDA208.76-3.30 (-1.56%) ▼|ORCL120.04-5.80 (-4.61%) ▼|PEP134.95-0.70 (-0.52%) ▼|PFE25.01+0.19 (+0.77%) ▲|PG146.97-2.16 (-1.45%) ▼|PLTR123.37-1.20 (-0.96%) ▼|PM191.12-3.18 (-1.64%) ▼|QCOM171.11-4.52 (-2.57%) ▼|RTX209.16+14.28 (+7.33%) ▲|SBUX103.21-0.77 (-0.74%) ▼|SCHW101.61+0.81 (+0.80%) ▲|SO96.60+0.80 (+0.84%) ▲|SPG225.20-1.02 (-0.45%) ▼|T22.96-0.08 (-0.35%) ▼|TMO572.32+45.86 (+8.71%) ▲|TMUS170.42-20.52 (-10.75%) ▼|TSLA319.69-54.32 (-14.52%) ▼|TXN284.99-9.20 (-3.13%) ▼|UBER68.91-1.42 (-2.02%) ▼|UNH423.56-7.75 (-1.80%) ▼|UNP304.33+11.77 (+4.02%) ▲|UPS114.10-1.74 (-1.50%) ▼|USB63.33-1.14 (-1.77%) ▼|V351.60-1.82 (-0.52%) ▼|VZ43.82-0.47 (-1.06%) ▼|WFC86.19-0.23 (-0.27%) ▼|WMT108.40-0.93 (-0.85%) ▼|XOM156.89+2.44 (+1.58%) ▲|

21.4 C

New York

Friday, July 24, 2026

MaxsMaking Inc. Announces Receipt of Nasdaq Delisting Determination Notice

LG INSTAVIEW™ REFRIGERATOR SURPASSES 5.3 MILLION IN GLOBAL SALES

Luvme Hair Announces Expert Guide to Human Hair Crochet Extension Quality

Tag: drug design

Evaxion receives Prix Galien UK Award for Best digital health solution

COPENHAGEN, Denmark, June 12, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, has been awarded the 2026 Prix Galien UK Award for Best digital health solution for AI-Immunology™.

Lynk Pharmaceuticals’ Partner Formation Bio Doses First Participant in Phase 1 Trial of BLKR201 (originally designated as LNK01006), a CNS-Penetrant TYK2 Inhibitor

HANGZHOU, China, SHANGHAI and BOSTON, June 10, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on...

Everest Medicines Enters into Exclusive Asia-Pacific Licensing Agreement with Vcare PharmaTech for Sumecigrel

SHANGHAI, June 9, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing,...

Ambrosia Biosciences Announces Preclinical Data Supporting Differentiated Profile of AMB-702, its Novel Small Molecule GLP-1 Receptor Agonist Development Candidate

AMB-702 demonstrates superior target coverage and efficacy in lean non-human primates The dataset was shared as part of a poster presentation at the American Diabetes...

Eratrectinib, the next-generation TRK inhibitor independently developed by Vcare PharmaTech, has received marketing approval

NANJING, China, June 5, 2026 /PRNewswire/ -- NTRK gene fusions have been identified as oncogenic drivers in adult and pediatric patients with pan-solid tumors....

【COMPUTEX 2026】Compal Integrates Quantum Technology and AI – Partnering with Top Universities and Pharmaceutical Firms to Build a Biotech AI Platform

TAIPEI, June 4, 2026 /PRNewswire/ -- Compal Electronics (Compal; TWSE: 2324) showcases its landmark achievements in Quantum Technology and Advanced Artificial Intelligence (AI) at COMPUTEX...

Tyra Biosciences Reports Second Quarter 2025 Financial Results and Highlights

- Dosed first patient in SURF302 for intermediate risk non-muscle invasive bladder cancer (IR NMIBC) - - Cash, cash equivalents, and marketable securities of $296.3...

Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results

Initiated rolling NDA submission for zidesamtinib for TKI pre-treated patients with advanced ROS1-positive NSCLC, with target completion in the third quarter of 2025 Initiated ALKAZAR...

Innovent Receives U.S. FDA Approval for IND Application of Oral GLP-1R Agonist IBI3032

SAN FRANCISCO and SUZHOU, China, Aug. 4, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality...

Blacksmith Medicines Co-Founder Presents at the 21st International Conference on Biological Inorganic Chemistry

Presentation highlights Blacksmith's novel chemistry platform for targeting metalloenzymes and FG-2101, a first-in-class non-hydroxamate LpxC inhibitor SAN DIEGO, Aug. 1, 2025 /PRNewswire/ -- Blacksmith Medicines,...

Atombeat and BioDuro Announce Strategic Partnership to Launch an AI-Powered Platform for Accelerated Peptide Drug Discovery

SAN DIEGO, Aug. 1, 2025 /PRNewswire/ -- On July 30, 2025, Atombeat Inc., a leading force in AI for drug discovery, and BioDuro, a...

VedTechBio Unveils Next-Gen Drug Discovery AI; Partners with AlphaMeld in Multi-Therapy Collaboration

VedTechBio enhances RxAgentAI platform; teams with US-based AlphaMeld to cut drug discovery time and co-develop therapies for rare and metabolic diseases.

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Company Name

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Name

This field is for validation purposes and should be left unchanged.

HomeTagsDrug design